EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Nanomedicine for Precision Insulin Delivery

Alfredo Caturano iD, Roberto Nilo, Davide Nilo iD, Vincenzo Russo iD, Erica Santonastaso, Raffaele Galiero iD, Luca Rinaldi, Marcellino Monda iD, Celestino Sardu iD, Raffaele Marfella iD, Ferdinando Carlo Sasso iD

Pharmaceuticals · 15.07.2024 · 17 (7) · 945

DOI: 10.3390/ph17070945 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 15.07.2024. Verfasst von Alfredo Caturano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus, which comprises a group of metabolic disorders affecting carbohydrate metabolism, is characterized by improper glucose utilization and excessive production, leading to hyperglycemia. The global prevalence of diabetes is rising, with projections indicating it will affect 783.2 million people by 2045. Insulin treatment is crucial, especially for type 1 diabetes, due to the lack of β-cell function. Intensive insulin therapy, involving multiple daily injections or continuous subcutaneous insulin infusion, has proven effective in reducing microvascular complications but poses a higher risk of severe hypoglycemia. Recent advancements in insulin formulations and delivery methods, such as ultra-rapid-acting analogs and inhaled insulin, offer potential benefits in terms of reducing hypoglycemia and improving glycemic control. However, the traditional subcutaneous injection method has drawbacks, including patient compliance issues and associated complications. Nanomedicine presents innovative solutions to these challenges, offering promising avenues for overcoming current drug limitations, enhancing cellular uptake, and improving pharmacokinetics and pharmacodynamics. Various nanocarriers, including liposomes, chitosan, and PLGA, provide protection against enzymatic degradation, improving drug stability and controlled release. These nanocarriers offer unique advantages, ranging from enhanced bioavailability and sustained release to specific targeting capabilities. While oral insulin delivery is being explored for better patient adherence and cost-effectiveness, other nanomedicine-based methods also show promise in improving delivery efficiency and patient outcomes. Safety concerns, including potential toxicity and immunogenicity issues, must be addressed, with the FDA providing guidance for the safe development of nanotechnology-based products. Future directions in nanomedicine will focus on creating next-generation nanocarriers with precise targeting, real-time monitoring, and stimuli-responsive features to optimize diabetes treatment outcomes and patient safety. This review delves into the current state of nanomedicine for insulin delivery, examining various types of nanocarriers and their mechanisms of action, and discussing the challenges and future directions in developing safe and effective nanomedicine-based therapies for diabetes management.

Schlagwörter

Stichwörter der Autor:innen

insulinnanomedicinenext-generation nanocarriersprecision insulin deliverytargeted drug delivery

Autor:innen und Institutionen

  • Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Department of Experimental Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Data Collection G-STeP Research Core Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
  • Department of Biology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA 19122, USA.
  • Division of Cardiology, Department of Medical Translational Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Independent Researcher, 81024 Maddaloni, Italy.

ORCID-Profile: Alfredo Caturano, Davide Nilo, Vincenzo Russo, Raffaele Galiero, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso

Zitieren

APA

Caturano, A., Nilo, R., Nilo, D., Russo, V., Santonastaso, E., Galiero, R., Rinaldi, L., Monda, M., Sardu, C., Marfella, R., & Sasso, F. C. (2024). Advances in Nanomedicine for Precision Insulin Delivery. Pharmaceuticals, 17(7), 945. https://doi.org/10.3390/ph17070945

Vancouver

Caturano A, Nilo R, Nilo D, Russo V, Santonastaso E, Galiero R, et al. Advances in Nanomedicine for Precision Insulin Delivery. Pharmaceuticals. 2024;17(7):945. doi:10.3390/ph17070945

BibTeX
@article{Caturano2024,
  author = {Caturano, Alfredo and Nilo, Roberto and Nilo, Davide and Russo, Vincenzo and Santonastaso, Erica and Galiero, Raffaele and Rinaldi, Luca and Monda, Marcellino and Sardu, Celestino and Marfella, Raffaele and Sasso, Ferdinando Carlo},
  title = {Advances in Nanomedicine for Precision Insulin Delivery},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {7},
  pages = {945},
  doi = {10.3390/ph17070945}
}
Kostenlos starten →